Search clinical trials for: FMS-like tyrosine kinase receptor

Total 26250 results

Exelixis

Completed

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)

Hepatocellular Carcinoma

Belgium, Hong Kong, Korea, Republic of, Canada, France, Taiwan, United States, Germany, Spain, United Kingdom, Singapore, Australia, Italy, Netherlands, Poland, Turkey, Ireland, New Zealand, Romania
Exelixis

Completed

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR)

Renal Cell Carcinoma

United States, Belgium, Spain, Taiwan, Canada, Germany, Korea, Republic of, France, Austria, Chile, Australia, Hungary, Russian Federation, Italy, Turkey, Netherlands, Sweden, United Kingdom, Czechia, Ireland, Slovakia, Argentina, D... and more
Astellas Pharma Global Development, Inc.

Approved for marketing

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

United States, Canada, Japan
Daiichi Sankyo, Inc.

Completed

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

AML

United States, Korea, Republic of, Taiwan, United Kingdom, France, Australia, Spain, Italy, Canada, Singapore, Germany, Netherlands, Hong Kong, Belgium, Croatia, Czechia, Hungary, Poland, Serbia
AstraZeneca

Completed

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM)

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Australia
Bayer

Completed

Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body

Solid Tumors Harboring NTRK Fusion

Germany
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Boehringer Ingelheim

Completed

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
Ai Peng

Unknown

The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients

Hemodialysis Complication

China
ArQule, Inc. (a wholly owned subsidiary of Merck...

Terminated

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Ovarian Cancer | Endometrial Cancer | Solid Tumors

United States
Array Biopharma, now a wholly owned subsidiary...

Completed

A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers

Metastatic Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Completed

Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)

Breast Cancer

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

Colorectal Cancer | Colorectal Adenocarcinoma

United States
AVEO Pharmaceuticals, Inc.

Completed

A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma

Carcinoma, Renal Cell

Ukraine, India, Russian Federation
Daiichi Sankyo, Inc.

Completed

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Acute Myeloid Leukemia | Leukemia | AML | Myelodysplastic Syndrome | MDS

United States, Georgia
Seagen Inc.
Array BioPharma

Completed

A Study of ARRY-380 in Patients With Advanced HER2+ Cancer

Cancer

Canada, United States
National Cancer Institute (NCI)

Completed

Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors

GIST

United States
National Taiwan University Hospital

Completed

The Role of Protein Tyrosine Kinase 7 (PTK7) in Non-small Cell Lung Cancer

Tumor Progression

Taiwan
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer

United States
Janssen Research & Development, LLC

Completed

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China, Taiwan, Korea, Republic of
Bayer

Approved for marketing

Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Tumors Harboring NTRK Fusion
National Cancer Institute (NCI)

Terminated

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

Adenocarcinoma | Carcinoma, Squamous Cell | Carcinoma, Non-Small Cell Lung | Carcinoma, Large Cell

United States
Northwestern University
AVEO Pharmaceuticals, Inc.

Completed

A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma

United States
GlaxoSmithKline

Completed

A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers

Irritable Bowel Syndrome

Australia
Advenchen Laboratories, LLC

Terminated

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) (AL3818)

Cervical Cancer | Ovarian Cancer | Endometrial Cancer

United States
Assistance Publique - Hôpitaux de Paris

Completed

Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion" (TARGET)

Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion | Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion

France
Hoffmann-La Roche

Terminated

Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors (TITAN)

Advanced or Metastatic Solid Tumors

United States
Tesaro, Inc.

Completed

A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

Solid Tumors | Lymphomas

United Kingdom, United States, Taiwan, Spain, Poland
Eli Lilly and Company

Completed

A Study of IMC-RON8 in Advanced Solid Tumors

Cancer

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Non-Small-Cell Lung Cancer

Japan
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation

Completed

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation

Completed

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
Sierra Oncology, Inc.

Terminated

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

United States
Haihua Yang

Unknown

Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Clifford Hospital, Guangzhou, China

Unknown

Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

Carcinoma, Non-Small-Cell Lung

China
Astellas Pharma Inc

Terminated

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations

Japan
H. Lee Moffitt Cancer Center and Research Institute
Pfizer; National Comprehensive Cancer Network

Completed

A Study of Axitinib in Advanced Carcinoid Tumors

Carcinoid Tumor

United States
Astellas Pharma Global Development, Inc.

No longer available

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

Australia, Italy, United Kingdom
National Heart, Lung, and Blood Institute (NHLBI)

Withdrawn

Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease

Pulmonary Hypertension
Children's Oncology Group

Completed

VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors

Refractory or Recurrent Solid Tumors, Excluding CNS Tumors

United States, Canada
AIO-Studien-gGmbH
AstraZeneca

Terminated

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

NSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR Mutation

Germany
Masonic Cancer Center, University of Minnesota

Terminated

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

Leukemia

United States
Manmeet Ahluwalia, MD
National Cancer Institute (NCI); Novartis

Completed

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Withdrawn

Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma
M.D. Anderson Cancer Center
OSI Pharmaceuticals

Terminated

Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

Skin Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Bayer; Genzyme, a Sanofi Company; Amgen; Georgia...

Completed

Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

Leukemia | Acute Myelogenous Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Carcinoma

United States
GlaxoSmithKline

Completed

A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects

Irritable Bowel Syndrome

Australia
Zaiwen Fan

Unknown

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Advanced Cancer | Lung Cancer, Nonsmall Cell
Sun Yat-sen University
Hangzhou ACEA Pharmaceutical Research Co., Ltd.; Acea Bio (Hangzhou) Co., Ltd.

Unknown

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
Genzyme, a Sanofi Company

Completed

Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer

Multiple Myeloma

United States, Canada

Search clinical trials for: FMS-like tyrosine kinase receptor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations